Recipient demographic and pre-operative characteristics.

<p>Data are presented as number (percentage), median (IRQ), or mean ± standard deviation.</p>†<p>Independent t-test;</p>‡<p>Wilcoxon rank sum test;</p>¶<p>Chi-square test;</p>§<p>Fisher’s exact test.</p>1<p>Two subjects in basiliximab group and three in the steroid group were missing data.</p>2<p>One subject in basiliximab group was missing data.</p><p>AFP = alpha-fetoprotein; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IQR = interquartile range; SD, standard deviation; UCSF, University of California San Francisco.</p

Recipients with acute rejection.

<p>Data are presented as number (percentage).</p>a<p>Glucocorticoid treatment consisted of oral methylprednisolone or oral prednisone.</p>†<p>Chi-square test;</p>‡<p>Fisher’s exact test.</p><p>MMF = mycophenolate mofetil, NA = non-available.</p

Recipient postoperative status, complications, and immunosuppressive therapy^a.

<p>Data are presented as number (percentage), median (IRQ), or mean ± standard deviation.</p>a<p>The number of patients for the basiliximab and steroid groups are 78 and 100, respectively unless indicated otherwise.</p>b<p>The number of patients for the basiliximab and steroid groups are 44 and 58, respectively.</p>†<p>Wilcoxon rank sum test;</p>‡<p>Chi-square test;</p>¶<p>Fisher’s exact test;</p>§<p>independent t-test.</p><p>CMV = cytomegalovirus; GVHD = graft versus host disease; MMF = mycophenolate mofetil; NA = not available; PTLD = post-transplant lymphoproliferative disorder.</p

Recipients with HCC Recurrence^a.

<p>Data are presented as number (percentage).</p>a<p>The number of patients for basiliximab and steroid groups are 78 and 100, respectively unless indicated otherwise.</p>†<p>Chi-square test;</p>‡<p>Fisher’s exact test. NA: non-available.</p>b<p>Four subjects in the basiliximab group and 6 subjects in the steroid group had missing data.</p>c<p>One subject in the basiliximab group was missing data.</p><p>HCC = hepatocellular carcinoma.</p

Overall survival of recipients between basiliximab and steroid groups (log-rank test, <i>P = </i>0.734).

<p>Overall survival of recipients between basiliximab and steroid groups (log-rank test, <i>P = </i>0.734).</p

Cox proportional hazard regression model for disease-free survival.

1<p>n = 173;</p>2<p>n = 177.</p>†<p>In the multivariate model, data of 173 subjects were included.</p><p>AFP = alpha-fetoprotein; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; UCSF, University of California San Francisco.</p

Disease-free survival between basiliximab and steroid groups for (A) all recipients (log-rank test, <i>P = </i>0.913); (B) recipients within Milan criteria (log-rank test, <i>P = </i>0.022); (C) recipients within UCSF criteria (log-rank test, <i>P = </i>0.079).

<p>Disease-free survival between basiliximab and steroid groups for (A) all recipients (log-rank test, <i>P = </i>0.913); (B) recipients within Milan criteria (log-rank test, <i>P = </i>0.022); (C) recipients within UCSF criteria (log-rank test, <i>P = </i>0.079).</p

Experimental valve quality and spring stiffness.

<p>C, spring stiffness; m, the quality of valve body.</p><p>Experimental valve quality and spring stiffness.</p

Curve of valve motion as a function of time with different valve masses.

<p>a) Displacement curve comparison; (b) velocity curve comparison.</p

Test principle diagram of valve motion.

<p>1) Torque speed sensor; 2) angular displacement sensor; 3) inhalation flow sensor; 4) temperature sensor; 5) pressure sensor; 6) displacement sensor; 7) vibration sensor; 8) discharge pressure sensor; 9) discharge flow sensor; 10) temperature sensor.</p